Fertility
Clue and Johns Hopkins researchers unveil largest study on menstrual cycle, mood and gastrointestinal symptoms

Clue, the menstrual and reproductive health tracking app, has announced the results of the largest study to date, examining the relationship between gastrointestinal (GI) symptoms, mood and the menstrual cycle.
Led by researchers at Johns Hopkins University, the new study provides important insights into the complex link between GI and mood symptoms across the menstrual cycle, particularly for individuals with premenstrual syndrome (PMS).
The study analysed data from more than 33,000 menstrual cycles over a four year period, across more than 32,000 participants, making it the most comprehensive study of its kind.
Participants used Clue’s menstrual tracking app to identify and track their symptoms and opted-in to share their data anonymously for research.
Key findings:
GI symptoms such as bloating, constipation, diarrhea, and nausea were more frequently tracked in the days leading up to menstruation as compared to the days following it, with a stronger effect observed in those with PMS.
A strong positive association was found between mood symptoms and GI symptoms across all phases of the menstrual cycle, for both PMS and non-PMS groups, indicating that these symptoms often occur together.
Participants with self-reported PMS tracked more GI symptoms throughout their entire menstrual cycle compared to those without PMS.
Amanda Shea, Fractional Chief Science Officer at Clue, said: “At Clue, we’re committed to advancing society’s understanding of menstrual health through data-driven research.
These findings not only validate the experiences of millions of women and people with cycles, but also pave the way for more effective support and treatment during especially difficult times of their menstrual cycle.”
With the Clue app, members can track when they feel bloated or gassy, monitor constipation or diarrhea, and log mood fluctuations throughout their cycle.
By customising additional tags, members can capture their unique experiences, and get a clear overview of how gastrointestinal symptoms and mood changes interact during their cycles.
Shea said: “Reporting your experiences and discomforts to your healthcare provider from memory alone often doesn’t reflect the true condition of your health and might not be the most reliable.
“We recommend tracking both your digestion and feelings daily, and over a longer period, to help you and your healthcare provider analyse cycle-related patterns.”
Liisa Hantsoo, Ph.D. is Assistant Professor in Psychiatry and Behavioral Sciences at the Johns Hopkins School of Medicine, and Director of Research in the Johns Hopkins Reproductive Mental Health Center.
Hantsoo said: “This study was exciting because it drew from such a large dataset of menstrual cycles, to give a representative look at GI symptoms and mood across the cycle.
“We were able to see a clear relationship between GI symptoms and mood at multiple points in the menstrual cycle.
“Previous studies have found links between GI symptoms and mood in people with major depression, but this had not been assessed in the context of the menstrual cycle or premenstrual mood symptoms.
“We hope this study leads to more research on the gut-brain axis in the context of menstrual health.”
The full study can be found here.
Fertility
AI could transform ovarian care through personalisation, study finds

AI could transform ovarian care by personalising cancer and fertility treatment, but more clinical validation is needed before routine use.
A systematic review and meta-analysis found AI models showed high diagnostic accuracy for ovarian cancer when combining data such as ultrasound scans and blood test results.
Across 81 studies, AI models correctly identified ovarian cancer in around nine out of 10 cases, with pooled rates of 89 to 94 per cent.
They were also highly accurate at ruling out ovarian cancer when it was not present, with specificity of 85 to 91 per cent.
The analysis also found that explainable AI tools could predict complete surgical cytoreduction in advanced ovarian cancer.
Complete surgical cytoreduction means removing all visible cancer during surgery, which can be an important goal in treatment planning.
The tools achieved a pooled AUC of 0.87. AUC is a measure of how well a model distinguishes between different outcomes, with higher scores showing stronger performance.
In reproductive medicine, AI algorithms helped physicians optimise ovarian stimulation protocols and predict follicular growth during IVF.
Ovarian stimulation is the use of hormones to encourage the ovaries to produce eggs, while follicles are the small sacs in the ovaries where eggs develop.
The review found AI could reliably model ovarian response in IVF with a pooled AUC of 0.81.
However, researchers said challenges remain in translating promising research findings into routine clinical practice.
They identified substantial variation across studies, driven by retrospective study designs, variable AI systems and a lack of standardised validation.
Only 22 per cent of analysed studies reported prospective, multicentre external validation, where models are tested forward in time across multiple healthcare settings.
The authors called for rigorous validation to help close the gap between research and routine clinical practice, alongside standardised methodological and reporting frameworks, smooth integration with clinical workflow and robust governance to support responsible and ethical AI use.
They concluded: “Artificial intelligence is a transformative force in the management of ovarian conditions.
“In gynaecologic oncology, AI enhances every phase of care, from early detection and accurate diagnosis to prognostic stratification and surgical planning.”
In reproductive medicine, AI personalises ovarian stimulation and refines the diagnosis of heterogenous endocrine disorders such as PCOS.
PCOS, or polycystic ovary syndrome, is a hormonal condition that can affect periods, skin, weight and fertility.
Fertility
Housing, work and fertility stop Britons having the families they want – research
Fertility
Femtech World reveals fertility innovation award shortlist

Femtech World is thrilled to reveal the shortlist for the Fertility Innovation Award.
The award, sponsored by FinDBest IVF, celebrates a pioneering product, service or initiative that is transforming fertility care and support.
FinDBest IVF is a global B2B digital platform created to simplify and accelerate how IVF and ART manufacturers connect with trusted, pre-vetted distributors around the world.
This year’s nominees represent a remarkable breadth of approaches to fertility care: from clinic-floor breakthroughs to at-home hormone intelligence to truly borderless access.
Three companies made the cut, with each tackling a real, persistent barrier in reproductive health.
Congratulations to the shortlist and many thanks to everyone who entered.
Fertility Innovation Award Shortlist

HRC Fertility’s Needle-Free IVF is a pioneering advancement designed to transform one of the most challenging aspects of fertility treatment: daily hormone injections.
Developed by board-certified reproductive endocrinologist Dr Rachel Mandelbaum, this innovative approach reimagines how stimulation medications are delivered during IVF and egg freezing, dramatically improving the patient experience while maintaining the same trusted clinical outcomes.
Inspired by feedback from patients who struggled with the injection process, Dr Mandelbaum adapted an innovative drug-delivery system commonly used in other areas of medicine and applied it to reproductive care

Mira is a hormonal health technology company that provides lab-grade hormone testing and AI-driven insights to help women and couples understand their fertility.
The platform has already supported more than 200,000 couples on their fertility journeys worldwide, helping over 60,000+ users achieve pregnancy.
For some users, pregnancy rates have reached up to 89 per cent within six months, demonstrating how accurate hormone data can significantly improve fertility outcomes.

Founded in 2021 by Marija Skujina, a Certified Fertility Nurse Specialist accredited by the European Society of Human Reproduction and Embryology, with nearly 15 years of clinical experience at one of the world’s top IVF clinics, and having navigated her own fertility journey as a patient, Marija built the clinic she had always wished existed.
Plan Your Baby began with a bold, but simple mission – make best quality fertility and pregnancy available anywhere.
Plan Your Baby has created a new generation fertility and pregnancy clinic with patients accessing expert consultations remotely, while blood tests and ultrasound scans are available at over 450 locations across the UK, eliminating the exhausting travel burden that often forces people to take days off work, relocate appointments, or abandon treatment altogether
What happens now
The shortlist will be judged by a representative from category sponsor FindBestIVF, with the winner announced at a virtual event on June 19.
Winners will receive a trophy and be interviewed by a Femtech World journalist.
Entrepreneur3 weeks agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
News3 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Diagnosis3 weeks agoNew meta-analysis further supports low re-excisions and high placement accuracy with the Magseed marker
Diagnosis3 weeks agoNIPT or NT scan? Why the 2026 evidence supports doing Both
Mental health4 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
Menopause4 weeks agoResistance training has preventative effects in menopause, study finds
Wellness2 weeks agoWomen’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage
Insight3 weeks agoWhy the UK’s fertility rate keeps falling – and what it means if you’re trying now







